One heart drug is enough, Novartis has signaled to Akcea. The Swiss drugmaker tied up with the antisense company, and close affiliate Ionis, in 2017. The exclusive option agreement — to develop and commercialize AKCEA-APO(a)-L and AKCEA-APOCIII-L — granted Ionis and Akcea $75 million upfront, in addition to milestone payments
FDA vaccine advisors unanimously recommend JN.1-lineage Covid-19 vaccine for upcoming season. CBER Director Vinay Prasad emphasizes transparency in vaccine discussions.
Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the 23andMe deal as worthwhile.
Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO’s disease cure claims.
The FDA’s Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer.
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates for different age groups, including higher risk in young…
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates for different age groups, including higher risk in young…
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines…
Biotech execs express concerns over FDA changes, NIH cuts, and Trump’s tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.
Biotech execs express concerns over FDA changes, NIH cuts, and Trump’s tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.
Americans live shorter and less healthy lives than people in other high-income countries.
